Slow growth forecast for asthma therapeutics market to 2018

The global asthma therapeutics market was valued at $14.4 billion in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 4.6% over the next eight years, to reach $20.6 billion by 2018, according to a new report from GlobalData.

The asthma therapeutics market has registered high growth during 2005 to 2010. This is due to the growth in the patient population during 2005-2010 as well as the preferential uptake of novel products such as Advair/Seretide and Symbicort; the global asthma therapeutics market grew at a compound annual growth rate (CAGR) of 11.2% between 2005 and 2010.

The current asthma therapeutics market has strong presence of three brands namely, Advair/Seretide (fluticasone propionate and salmeterol), Symbicort (budesonide/formoterol fumarate) and Singulair (montelukast sodium). These brands account for more than half of the revenue of the total asthma market in 2010. Inhaled corticosteroid/long-acting beta agonists (ICS/LABA) combinations constitute the leading drug classes in terms of market value. These treatment options are set to remain the dominant classes during the forecast period until 2018.